Diroximel fumarate brain health study for schizophrenia
Treatments studied
Part of Mental health clinical trials.
This trial tests if a drug called diroximel fumarate can help increase a natural antioxidant (glutathione) in the brain for people with schizophrenia. It aims to see if lowering inflammation and boosting brain protection might improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old and have been diagnosed with schizophrenia.
- Your antipsychotic medication has been stable for at least 1 month.
- You have had no serious worsening of symptoms in the last 2 months.
- You score at least 60 on a standard symptom scale (PANSS).
- You are not pregnant, breastfeeding, or planning pregnancy, and if you could become pregnant you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called daridorexant, which affects the brain's sleep-wake system, to see how it influences emotions and thinking. You will take one dose and complete computer tasks that measure how you process emotional information.
This trial tests an experimental combination treatment that targets two different brain receptors (sigma-1 and NMDA) to see if it can improve symptoms in people with schizophrenia that hasn't responded well to standard antipsychotics.
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
This trial tests two medicines, deferiprone and N-acetylcysteine, taken together to see if they improve negative symptoms of schizophrenia, such as lack of motivation or pleasure. It aims to find a new option for people who still have these symptoms despite their current antipsychotic treatment.
This study looks at how a specific type of brain receptor (dopamine-3) works in people with schizophrenia using special brain scans (PET). Researchers want to see how these receptors behave when you are not taking antipsychotic medication, which may help guide future treatments.
This study tests whether brilaroxazine works and is safe for people with schizophrenia. It mainly aims to help people whose symptoms are still present despite prior treatment, while excluding those with certain other diagnoses or substance/drug issues.
Hear when a new Schizophrenia Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.